menu search

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in progress to facilitate patient enrollment and dosing OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of […] The post AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients appe... Read More
Posted: Feb 28 2023, 13:45
Author Name: forextv
Views: 102046

Search within

Pages Search Results: